The Securities and Exchange Commission has not necessarily
reviewed the information in this filing and has not determined
if it is accurate and complete.
| |||||||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| BICYCLE THERAPEUTICS PLC | SPONSORED ADS | 088786108 | 6,485,339 | 1,529,561 | SH | SOLE | 1,529,561 | 0 | 0 | ||
| BIONTECH SE | SPONSORED ADS | 09075V102 | 82,798,123 | 889,824 | SH | SOLE | 889,824 | 0 | 0 | ||
| CRISPR THERAPEUTICS AG | NAMEN AKT | H17182108 | 175,652,997 | 3,220,627 | SH | SOLE | 3,220,627 | 0 | 0 | ||
| CVRX INC | COM | 126638105 | 5,178,977 | 1,007,583 | SH | SOLE | 1,007,583 | 0 | 0 | ||
| CYTOKINETICS INC | COM NEW | 23282W605 | 29,001,573 | 340,434 | SH | SOLE | 340,434 | 0 | 0 | ||
| FULCRUM THERAPEUTICS INC | COM | 359616109 | 6,535,713 | 1,785,714 | SH | SOLE | 1,785,714 | 0 | 0 | ||
| IDEAYA BIOSCIENCES INC | COM | 45166A102 | 49,693,321 | 1,333,333 | SH | SOLE | 1,333,333 | 0 | 0 | ||
| LYELL IMMUNOPHARMA INC | COM NEW | 55083R203 | 21,252,859 | 1,512,659 | SH | SOLE | 1,512,659 | 0 | 0 | ||
| NKARTA INC | COM | 65487U108 | 8,916,572 | 3,150,732 | SH | SOLE | 3,150,732 | 0 | 0 | ||
| REGENXBIO INC | COM | 75901B107 | 3,252,043 | 271,456 | SH | SOLE | 271,456 | 0 | 0 | ||
| SPERO THERAPEUTICS INC | COM | 84833T103 | 20,311,239 | 9,190,606 | SH | SOLE | 9,190,606 | 0 | 0 | ||
| VIR BIOTECHNOLOGY INC | COM | 92764N102 | 87,134,221 | 8,550,954 | SH | SOLE | 8,550,954 | 0 | 0 | ||
| WAVE LIFE SCIENCES LTD | SHS | Y95308105 | 106,007,465 | 18,245,691 | SH | SOLE | 18,245,691 | 0 | 0 | ||